Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the
treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib …

Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of
Bruton's tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell …

Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential
effector of B-cell receptor (BCR) signaling. Chronic activation of BTK-mediated BCR …

The upfront treatment of very elderly and frail patients with diffuse large B-cell lymphoma
(DLBCL) is still a matter of debate. Herein, we report results of the metronomic all-oral …

Diffuse large B-cell lymphoma (DLBCL) represents the commonest subtype of non-Hodgkin
lymphoma and encompasses a group of diverse disease entities, each harboring unique …

Abstract The International prognostic Index (IPI) is the most widely used clinical prediction
model for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab …

Introduction: Diffuse large B-cell lymphoma (DLBCL) is a common neoplasm in older
people; in this group, personalized therapies are important because while some patients are …

Very old and frail patients with diffuse large B-cell lymphoma (DLBCL) very commonly
present to physicians. However, this population is rarely included in clinical trials that …

Simple Summary The treatment choice for an older patient with diffuse large B-cell
lymphoma (DLBCL) is challenging due to the complexity of the patient. Among the several …

Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) has
demonstrated significant effectiveness in treating patients with diffuse large B-cell …